Glasgow Asthma and Allergy Study (GLAAS)

Cross Sectional Study to Evaluate and Associate Clinical and Laboratory Features of People With Allergic and Non-allergic Asthma

In the past, doctors separated people with asthma into two groups, those with "allergic asthma" (about 2/3rds of people) and those with "non-allergic asthma". These labels are not much used now as the treatments for all people with asthma don't depend on this classification. However, new treatments for asthma may become available and the classification may again become important. It could be useful for clinicians to know how to identify which patients are likely to benefit from particular treatments.

Additionally, some new blood tests are becoming available and some of these might help to categorise the type of asthma people have. What the study hopes to do is to identify patient features which make a diagnosis of "allergic asthma" more likely and to see which new blood tests are most likely to be helpful in confirming this diagnosis.

Study Overview

• Status: Completed
• Conditions: Asthma; Allergy

• Study Type: Observational
• Enrollment (Actual): 105

Contacts and Locations

Study Locations

• United Kingdom
  • Kent
    • Dartford, Kent, United Kingdom, DA1 5GA
      • NSHI Ltd

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

• Sampling Method: Non-Probability Sample

Study Population

People with asthma, non smoker, aged 18 and over.

Description

Inclusion Criteria:

• Male and female patients aged 18 years old and over with a diagnosis of asthma and having received at least two prescriptions for any asthma medication in the last 12 months, who have signed an informed consent form prior to initiation of any study-related procedure

Exclusion Criteria:

• under 18 years
• current smokers
• unwilling or unable to give informed consent
• a clinical diagnosis of COPD
• a history of anaphylaxis (skin prick test)
• participated in any clinical study in the last 12 months

Study Plan

How is the study designed?

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort
General asthma population; People with asthma, aged 18 years and over, non smoker, all severities of disease, regardless of treatment, broad inclusion and few exclusion criteria.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Serum periostin level	This is a cross sectional study. Participants will be assessed and tests conducted at a single visit	1 day

Secondary Outcome Measures

Outcome Measure	Time Frame
skin prick test	1 day
Serum total IgE	1 day
Blood eosinophil count	1 day
Blood neutrophil count	1 day
Blood CD4 cells that are positive for CRTh2	1 day
Blood eosinophils expressing CRTh2	1 day
Spirometry	1 day

Collaborators and Investigators

• Sponsor: National Services for Health Improvement Ltd
• Collaborators: Merck Sharp & Dohme LLC
• Investigators: Principal Investigator: John A Haughney, MB ChB, NSHI Ltd

Study record dates

Study Major Dates

• Study Start: June 1, 2012
• Primary Completion (Actual): October 1, 2013
• Study Completion (Actual): October 1, 2013

Study Registration Dates

• First Submitted: June 8, 2012
• First Submitted That Met QC Criteria: June 12, 2012
• First Posted (Estimate): June 13, 2012

Study Record Updates

• Last Update Posted (Estimate): December 5, 2013
• Last Update Submitted That Met QC Criteria: December 4, 2013
• Last Verified: December 1, 2013

More Information

Terms related to this study

• Keywords: Asthma; Allergy; Diagnosis; Correlation study
• Additional Relevant MeSH Terms: Respiratory Tract Diseases; Immune System Diseases; Lung Diseases; Hypersensitivity, Immediate; Bronchial Diseases; Lung Diseases, Obstructive; Respiratory Hypersensitivity; Hypersensitivity; Asthma
• Other Study ID Numbers: 12/WS/0049